EndoChoice

About EndoChoice

EndoChoice, established in 2008, carved a niche for itself in the medical technology sector with a specific focus on gastroenterology. The company was founded by Mark Gilreath, an executive with a robust background in the medical device industry, including leadership roles at Given Imaging. This experience directly informed EndoChoice's strategy to create an integrated platform for gastroenterologists.

Operating from the greater Atlanta area, the company engineered a business model centered on providing a comprehensive suite of products and services. This portfolio included endoscopic imaging systems, single-use devices, and infection control products, effectively creating a one-stop shop for GI specialists. The firm's revenue was generated through the direct sale of these products to a customer base exceeding 2,500 in the United States, supplemented by a network of distribution partners in 25 other countries.

A cornerstone of its product lineup was the Full Spectrum Endoscopy (Fuse®) system. This technology differentiated itself by offering a panoramic 330-degree field of view during colonoscopies, a significant expansion compared to the 170-degree view of traditional forward-viewing colonoscopes. The stated benefit was an improvement in adenoma detection rates, a critical factor in the early identification of potential precursors to colorectal cancer. This was a key selling proposition, aiming to enhance diagnostic accuracy for physicians. In 2015, EndoChoice solidified its market position by going public on the New York Stock Exchange under the ticker symbol GI, raising approximately $96 million in its initial public offering. This milestone provided the capital to further expand its commercial operations and research and development efforts. The company's trajectory culminated in its acquisition by Boston Scientific in 2016 for approximately $210 million, at which point its operations were integrated into the larger corporation's endoscopy division.